BioPontis Aims To Bridge "Valley Of Death"
This article was originally published in Start Up
Executive Summary
BioPontis Alliance, a two-year old investment group, has been set up as a virtual network with the aim of introducing a new model for bridging the "valley of death" funding gap for early stage translational research. Its mission: to get more great science translated out of academia, say founders.
You may also be interested in...
Deals of the Week: Stada/Grunenthal, Stada/Spirig, Shire/Sangamo
While 2012 promises to be a lucrative for generic drug companies, they now face their own reverse patent cliff. Some, therefore, are looking to diversify into branded products.
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.